Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

What Was Tested

The paper reports a study of Triptorelin, published as a clinical trial, phase iii.

The primary objective was to model the urinary PCA3 change at 6 months, according to baseline variables.

Who Took Part

The study group was 5 men.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.

How the Study Was Run

In design terms this was a open-label and multicenter study.

Being open-label, the Triptorelin study did not mask who received what.

Running at several centres spread the Triptorelin study over different clinics and patient groups.

Other outcome measures included urinary PCA3 and TMPRSS2-ERG scores and statuses, and serum testosterone and prostate-specific antigen (PSA) levels at baseline and at 1, 3 and 6 months after initiation of ADT.

Safety was assessed by recording adverse events and changes in laboratory parameters.

What Was Measured

The subject headings attached to it are Antigens, Neoplasm, Antineoplastic Agents, Hormonal, Oncogene Proteins, Fusion, Prostate-Specific Antigen, Prostatic Neoplasms, Testosterone and Triptorelin Pamoate.

The authors tagged it with the keywords GnRH agonist, PCA3, TMPRSS2-ERG, advanced prostate cancer and disease severity.

What This Means in Plain Language

The paper is an open-label and multicenter study of Triptorelin in 5 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (BJU international), a journal based in England.

More context: the Triptorelin compound page, all human trials.